The management approaches to dyskinesia vary from country to country.
Many Parkinson's disease (PD) patients treated with levodopa develop motor fluctuations and/or dyskinesia. This large, retrospective study was conducted to compare the prevalence and treatment of dyskinesia in PD patients in seven countries. A total of 380 physicians were interviewed and completed patient record forms retrospectively for their last 5 patients with dyskinesia (total 1,900). The overall prevalence of dyskinesia in PD patients was 34%, but the rate varied from 24 to 51% according to geographical location. This study showed that 51.0% of Japanese physicians and 50.6% of UK physicians were dissatisfied with current treatment strategies for dyskinesia. Regardless of geographical location, physicians were dissatisfied with the current treatment strategies for dyskinesia.
Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany. dirk.woitalla@ruhr-uni-bochum.de
Dirk
D
Woitalla
Thomas
T
Mueller
Hermann
H
Russ
Klaus
K
Hock
Doris-Anita
DA
Haeger
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019091:Critical Pathways; D003431:Cross-Cultural Comparison; D003430:Cross-Sectional Studies; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000453:epidemiology; D005060:Europe; D006801:Humans; D015994:Incidence; D007564:Japan; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014481:United States
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa